Methotrexate for treating rheumatoid arthritis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Lopez Olivo, Maria Angeles ^a   Siddhanamatha, Harish R ^a   Shea, Beverley ^b   Tugwell, Peter ^c   Wells, George A ^b   Suarez Almazor, Maria E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT; FOLIC ACID ANTAGONIST;

ABDOMINAL PAIN; ADVERSE EVENT; ALLERGIC REACTION; ALOPECIA; ANOREXIA; BACKACHE; CEREBROVASCULAR ACCIDENT; COUGHING; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPEPSIA; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRIP STRENGTH; HEADACHE; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; INTERSTITIAL PNEUMONIA; JOINT SWELLING; LUNG DISEASE; LUNG INFILTRATE; MONOTHERAPY; MORNING STIFFNESS; MOUTH ULCER; NAUSEA AND VOMITING; NIGHTMARE; PATIENT ASSESSMENT; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; PRODUCTIVITY; PROTEINURIA; PRURITUS; PSORIASIS; QUALITY OF LIFE; RASH; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SHORT FORM 36; SIDE EFFECT; SKIN DISEASE; STOMATITIS; SYSTEMATIC REVIEW; THORAX PAIN; WALKING; ARTHRITIS, RHEUMATOID; FEMALE; MALE; MEDICATION COMPLIANCE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; MALE; MEDICATION ADHERENCE; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84934931372     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000957.pub2     Document Type: Review

References (46)

1. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Annals of Internal Medicine 1985;103(4):489-96.
2. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Adverse experience with methotrexate during 176 weeks of a long-term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology 1990;17(12):1628-35.
3. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology 1989;16(3):313-20.
4. Jiang LD, Wang JY, Mei ZW, Ni LQ. Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology 1998;4:204-7.
5. Pinheiro GR, Helfenstein Junior M, Ferraz MB, Atra E. [A short-term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira 1993;39(2):91-4.
6. Schiff MH. Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology 1999;28 Suppl 112:31-5.
7. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 2000;43(3):495-505. [PUBMED: 10728741]
8. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al.Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine 1999;159(21):2542-50. [PUBMED: 10573044]
9. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al.Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 1999;42(9):1870-8. [PUBMED: 10513801]
10. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al.Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506-14. [PUBMED: 10728742]
11. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE. Efficacy of low-dose methotrexate in rheumatoid arthritis. New England Journal of Medicine 1985;312(13):818-22.
12. Alarcon GS, Billingsley LM, Clegg DO, Hardin JG, Klippel, Luggen ME, et al.Lack of association between HLA-DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism 1987;30(2):218-20.
13. Tugwell P, Bombardier C, Buchanan WW, Goldsmith C, Grace E, Bennett KJ, et al.Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Archives of Internal Medicine 1990;150(150):59-62.
14. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, et al.Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism 1985;28(7):721-30.
15. Cannon GW, Reading JC, Ward JR, Blonquist LJ, Collette LB. Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate. Scandinavian Journal of Rheumatology 1990;19:285-94.
16. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al.Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis and Rheumatism 2001;44(9):1984-92. [PUBMED: 11592358]
17. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al.Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases 2010;69(1):88-96. [PUBMED: 19297346]
18. Szanto E. Low-dose methotrexate in rheumatoid arthritis: effect and tolerance. An open trial and a double-blind randomized study. Scandinavian Journal of Rheumatology 1986;15:97-102.
19. Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. Journal of Rheumatology 1984;11:760-3.
20. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. Journal of Rheumatology 1998;25(2):238-42. [PUBMED: 9489813]
21. Aga AB, Lie E, Uhlig T, Olsen IC, Wierød A, Kalstad S, et al.Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Annals of the Rheumatic Diseases 2013;Nov 27:epub. [doi: 10.1136/annrheumdis-2013-204020; PUBMED: 24285493]
22. Visual Rx [Computer program]. Version 3. Dr. Christopher Cates EBM web site 2008:URL: http://www.nntonline.net.
23. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91.
24. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials. Arthritis and Rheumatism 1992;35:1117-25.
25. Felson DT, Anderson JJ, Boers M, et al.The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism 1993;36:729-40.
26. Felson DT, Anderson JJ, Boers M, et al.American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1995;38:727-35.
27. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. Journal of Clinical Epidemiology 1992;45(6):587-94. [PUBMED: 1535101]
28. Groff BD, Shenberger KN, Wilke WS, Taylor TH. Low dose oral methotrexate in rheumatoid arthritis: An uncontrolled trial and review of the literature. Seminars in Arthritis and Rheumatism 1983;12:333-47.
29. Gubner R, August S, Ginsburg V. Therapeutic suppression of tissue reactivity.II. Effects of aminopterin in rheumatoid arthritis and psoriasis. American Journal of Medicine 1951;221(2):176-82.
30. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011). The Cochrane Collaboration 2011;Available from www.cochrane-handbook.org.:Accessed on: 09/16/2013.
31. Jadad A, Moore A, Carrol D, et al.Assessing the quality of reports of randomized trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
32. Kapral T, Stamm T, Machold KP, Montag K, Smolen JS, Aletaha D. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. Arthritis Research & Therapy 2006;8(2):R46. [PUBMED: 16507172]
33. Kazis LEE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Medical Care 1989;27(S3):S178-89.
34. Mueller PS1, Montori VM, Bassler D, Koenig BA, Guyatt GH. Ethical issues in stopping randomised trials early because of apparent benefit. Annals of Internal Medicine 2007;146(12):878-81. [PUBMED: 17577007]
35. OMERACT. Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Journal of Rheumatology 1993;20:526-91.
36. Petitti D. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. New York: Oxford University Press, 1994:90-114.
37. Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, et al.Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013;5(CD000951):doi: 10.1002/14651858.CD000951.pub2. [PUBMED: 23728635]
38. Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, et al.Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013;5:CD000951. [DOI: 10.1002/14651858.CD000951.pub2]
39. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al.2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research (Hoboken) 2012;64(5):625-39.
40. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases 2013;Oct 25:doi: 10.1136/annrheumdis-2013-204573.
41. Steinsson K, Weinstein A, Korn J, Abeles M. Low dose methotrexate in rheumatoid arthritis. Journal of Rheumatology 1982;9:860-6.
42. Todoerti M, Maglione W, Bernero E, Bortoluzzi A, Colaci M, Galuppi E, et al.Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis. Reumatismo 2013;65(5):207-18. [PUBMED: 24399184]
43. van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Annals of the Rheumatic Diseases 2005;64:1582-7.
44. van der Heijde D, Klareskog L, Landewé R, Bruyn GA, Cantagrel A, Durez P, et al.Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism 2007;56(1):3928-39. [PUBMED: 18050208]
45. Weinstein A, Marlowe S, Korn J, Farouhar F. Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations. American Journal of Medicine 1985;79(3):331-7. [PUBMED: 4036984]
46. Willkens RF, Watson MA, Paxson CS. Low dose pulse methotrexate therapy in rheumatoid arthritis. Journal of Rheumatology 1980;7:501-5.